

84. (New) The method of Claim 1, wherein the binding of said agent to said  $\alpha 5\beta 1$  integrin is at least ten-fold greater than the binding of said agent to an integrin other than  $\alpha 5\beta 1$  integrin.

85. (New) The method of Claim 84, wherein said integrin other than  $\alpha 5\beta 1$  integrin is  $\alpha V\beta 3$  integrin.

86. (New) The method of Claim 1, wherein said agent does not interfere with the specific binding of a ligand to an integrin other than  $\alpha 5\beta 1$  integrin.

87. (New) The method of Claim 1, wherein said tissue is in a human subject.

88. (New) The method of Claim 10, wherein said malignant neoplasm is selected from the group consisting of a sarcoma, a mesothelioma, a teratocarcinoma, an astrocytoma, and a glioblastoma.

89. (New) The method of Claim 12, wherein said carcinoma is selected from the group consisting of a breast carcinoma, a colon carcinoma, an ovarian carcinoma and a pancreatic carcinoma.

90. (New) The method of Claim 55, wherein the binding of said agent to said  $\alpha 5\beta 1$  integrin is at least two-fold greater than the binding of said agent to an integrin other than  $\alpha 5\beta 1$  integrin.

91. (New) The method of Claim 90, wherein said integrin other than  $\alpha 5\beta 1$  integrin is  $\alpha V\beta 3$  integrin.

92. (New) The method of Claim 55, wherein the binding of said agent to said  $\alpha 5\beta 1$  integrin is at least five-fold greater than the binding of said agent to an integrin other than  $\alpha 5\beta 1$  integrin.

93. (New) The method of Claim 92, wherein said integrin other than  $\alpha 5\beta 1$  integrin is  $\alpha V\beta 3$  integrin.

94. (New) The method of Claim 55, wherein the binding of said agent to said  $\alpha 5\beta 1$  integrin is at least ten-fold greater than the binding of said agent to an integrin other than  $\alpha 5\beta 1$  integrin.

95. (New) The method of Claim 94, wherein said integrin other than  $\alpha 5\beta 1$  integrin is  $\alpha V\beta 3$  integrin.

96. (New) The method of Claim 55, wherein said agent does not interfere with the specific binding of a ligand to an integrin other than  $\alpha 5\beta 1$  integrin.

97. (New) The method of Claim 55, wherein said ligand is fibronectin.

98. (New) The method of Claim 55, wherein said tissue comprises ocular tissue.

99. (New) The method of Claim 98, wherein said ocular tissue is selected from the group consisting of retina, macula and cornea.

100. (New) The method of Claim 55, wherein said tissue comprises a neoplasm.

101. (New) The method of Claim 100, wherein said neoplasm is a malignant neoplasm.

102. (New) The method of Claim 101, wherein said malignant neoplasm is selected from the group consisting of a sarcoma, a mesothelioma, a teratocarcinoma, an astrocytoma, and a glioblastoma.

103. (New) The method of Claim 101, wherein said malignant neoplasm is a metastatic malignant neoplasm.

104. (New) The method of Claim 101, wherein said malignant neoplasm is a carcinoma.

105. (New) The method of Claim 104, wherein said carcinoma is selected from the group consisting of a breast carcinoma, a colon carcinoma, an ovarian carcinoma and a pancreatic carcinoma.

Sub C17  
106. (New) The method of Claim 55, wherein said agent comprises a peptide.

A2 cont  
107. (New) The method of Claim 106, wherein said peptide comprises the amino acid sequence CRRETAWAC (SEQ ID NO: 1).

Sub C18  
108. (New) The method of Claim 55, wherein said agent is linked to a cytotoxin.

109. (New) The method of Claim 108, wherein said cytotoxin is a cancer chemotherapeutic drug.

Sub C19  
110. (New) The method of Claim 57, wherein the binding of said agent to said  $\alpha 5 \beta 1$  integrin is at least two-fold greater than the binding of said agent to an integrin other than  $\alpha 5 \beta 1$  integrin.

111. (New) The method of Claim 110, wherein said integrin other than  $\alpha 5 \beta 1$  integrin is  $\alpha V \beta 3$  integrin.

Sub C20  
112. (New) The method of Claim 57, wherein the binding of said agent to said  $\alpha 5 \beta 1$  integrin is at least five-fold greater than the binding of said agent to an integrin other than  $\alpha 5 \beta 1$  integrin.

113. (New) The method of Claim 112, wherein said integrin other than  $\alpha 5 \beta 1$  integrin is  $\alpha V \beta 3$  integrin.

Sub C21  
114. (New) The method of Claim 57, wherein the binding of said agent to said  $\alpha 5 \beta 1$  integrin is at least ten-fold greater than the binding of said agent to an integrin other than  $\alpha 5 \beta 1$  integrin.

A2 cont  
115. (New) The method of Claim 114, wherein said integrin other than  $\alpha 5 \beta 1$  integrin is  $\alpha V \beta 3$  integrin.

116. (New) The method of Claim 57, wherein said agent does not interfere with the specific binding of a ligand to an integrin other than  $\alpha 5 \beta 1$  integrin.

Sub C22  
117. (New) The method of Claim 57, wherein said agent comprises a peptide.

118. (New) The method of Claim 117, wherein said peptide comprises the amino acid sequence CRRETAWAC (SEQ ID NO: 1).

Sub C23  
119. (New) The method of Claim 57, wherein said agent is linked to a cytotoxin.

120. (New) The method of Claim 119, wherein said cytotoxin is a cancer chemotherapeutic drug.